18F-FDG,18f-fdgPet
18F-FDG,18f-fdgPet/ctImages
Accumulation,association
Accumulation,osteopontin-750Accumulation
Accumulation,strongAssociation
Accumulation,trendForLessRadicalSurgicalApproachesInBreastCancerDueBetterUnderstandingOfTumourBiology
Anti-HER2,additionalAnti-her2Therapy
Anti-HER2,anti-her2Therapy
Anti-HER2,neoadjuvantAnti-her2Treatment
Aspirin,aspirinUse
Aspirin,associationBetweenPost-diagnosisLow-doseAspirinUse
Aspirin,associationBetweenPost-diagnosisUseOfLow-doseAspirin
Aspirin,time-varyingPost-diagnosisLow-doseAspirinUse
Binding,binding
Binding,selectiveBinding
BRD4,brd4Inhibition
BRD4,brd4PharmacologicalInhibition
BRD4,brd4Regulation
Cardiotoxicities,theirCardiotoxicities
Case,case
Case,veryRareCaseOfTraumaticBreastNeuroma
Cases,24ApplicableCases
Cases,24Cases
Cases,allFiveCases
Cases,cases
Cases,feasibleInProperlySelectedCasesWithAsymptomaticNeuromasAfterAccurateTissueSampling
Cases,forty-threeCases
Cases,only35Cases
Cases,only35CasesOfTraumaticBreastNeuromas
Cases,veryRareClinicalEntityWithOnlyFewCasesHavingReportedToDate
Components,components
Components,specificCancerCell-relatedComponents
Contrast,availableContrastAgents
Contrast,contrastAfterInjection
Contrast,contrastAgents
Contrast,differentContrastAgent
Contrast,evidencedByIncreaseInContrastAfterInjection
Contrast,givenRecentConcernsAboutGadolinium-basedContrastAgentsAreAlsoInvestigatedForBreastCancerDiagnosis
Contrast,issuesOfExistingContrastAgents
Contrast,potentialOfAionAsEffectiveMultimodalContrastAgentForBreastCancerDiagnosis
Contrast,strongContrast
Contrast,strongContrastWithImagingModalities
Contrast,therapeuticApproachesEspeciallyUnderViewOfCurrentDevelopments
CTn,cTn
CTn,ctnLevels
CTn,inConclusionStillNecessaryForAdoptionOfCtnAsRoutineClinicalBiomarkerInPatientsWithBreastCancer
CTn,lowCtnLevels
Disease,acromegaly
Disease,AION
Disease,breastCancer
Disease,breastCancerDiagnosis
Disease,breastCancers
Disease,breastTumor
Disease,cancer
Disease,CBC
Disease,chestWallLesions
Disease,colorectalCancer
Disease,lungCancer
Disease,PA
Disease,seromaProduction
Disease,TNBC
Disease,triple-negativeBreastCancers
Excision,excision
Excision,oneYearOfDiseaseControlWithoutDeteriorationInHerEjectionFraction
Excision,surgicalExcision
Fluorescent,infraredFluorescentDye
Gene,BRCA1
Gene,CXCR4
HER2,aggressiveCourseOfHer2Cancer
HER2,elderlyPatientWithRelapsedHer2
Intake,associationBetweenIntakeOfB-carotene
Intake,intake
Intake,limitedEvidenceForSignificantlyInverseAssociationBetweenPrediagnosisDietaryIntakeOfB-caroteneAmongWomenWithBreastCancer
Intake,summaryHazardRatioOf070ForHighestIntake
IORT,IORT
Lesion,lesion
Lesion,mayIndicativeOfBenignLesion
Membrane,glycosylationOfMembraneTypeMr
Membrane,membraneTypeMannoseReceptor
Membrane,membraneTypeMr
Models,coxHazardRegressionModels
Models,coxProportionalHazardRegressionModels
MRI,costOfMriExamination
MRI,MRI
MRI,mriTechniques
MRI,unenhancedMriTechniques
MSOT,MSOT
MSOT,msotImaging
Neuromas,breastNeuromas
Neuromas,traumaticBreastNeuromas
Other,1
Other,12-15Percecnt
Other,12SampledWomen
Other,20PercecntIncreasedRiskOfBreastCancerAmongCurrentHormonalContraceptionUsers
Other,23Studies
Other,25Months
Other,25MonthsFromDiagnosis
Other,375Percecnt
Other,387Percecnt
Other,466Percecnt
Other,54Percecnt
Other,56Percecnt
Other,60Years
Other,68Ga-Pentixafor
Other,825Ml
Other,95PercecntConfidenceIntervals
Other,accomplished
Other,adjustment
Other,advancedDiagnosticImaging
Other,age
Other,agents
Other,ageOf25Years
Other,agreement
Other,aim
Other,Aims
Other,alsoShaped
Other,alternativeContrast-enhancedScreeningTools
Other,amongThemNewlyIdentifiedInStudy
Other,amount
Other,amountOfObservedVariationInSeromaProduction
Other,analysis
Other,analyzed
Other,Anthracyclines
Other,anti-her2Therapies
Other,apoptosis
Other,applied
Other,areInvestigated
Other,areUsed
Other,article
Other,asResultAreUsed
Other,at25HPost-injectionGreaterInTumorBedThanInKidneyRespectively
Other,BACKGROUND
Other,barcodeMode
Other,bcMortalityRates
Other,betterOutcomeWithGoodNegativePredictiveValue
Other,betterUnderstanding
Other,biomarker
Other,brca1Levels
Other,brca1Wild-typeTnbcCells
Other,brca1Wild-typeTripleNegativeBreastCancer
Other,brcanessPhenotype
Other,brcanessPhenotypeInBrca1Wild-typeTnbcCells
Other,Breast
Other,breastCancerPatientsSerum
Other,breastImagingModality
Other,cancerRiskPerception
Other,cardiacTroponins
Other,cellCycleRegulators
Other,clinicalBreastExamination
Other,clinicians
Other,cohortStudy
Other,combination
Other,combinationsOfInductionInBrca1Wild-typeTripleNegativeBreastCancer
Other,compared
Other,comparedSemi-quantitatively
Other,Comparison
Other,complex
Other,comprehensiveSearch
Other,concerns
Other,confirmed
Other,conservativeTreatment
Other,consistent
Other,contraceptionUse
Other,conventionalX-rayMammography
Other,copyright
Other,cornerstone
Other,correspondingCohort
Other,currentDevelopments
Other,currentUsersOfLongerDuration
Other,cxcr4ExpressionDeterminedByImmunohistochemistry
Other,decades
Other,decreases
Other,decreasesInBcMortalityRates
Other,denseBreasts
Other,designed
Other,detection
Other,detectionofBreastCancer
Other,detectionOfBreastCancerInWomen
Other,developed
Other,developedCbcDuring
Other,development
Other,diagnosed
Other,diagnosis
Other,diagnosisOfAcuteCoronarySyndromes
Other,diagnosisOfResponseToTreatment
Other,diagnosticEvaluation
Other,diet
Other,differentialDiagnosis
Other,differentialDiagnosisInPatientsWithHistoryOfBreastSurgery
Other,differentStudies
Other,directRelationship
Other,discovery
Other,discussed
Other,disease
Other,dnaDamage
Other,dose-dependentReduction
Other,dose-dependentReductionInBrca1Levels
Other,doses
Other,due
Other,effectiveDiagnosisOfBreastCancer
Other,Efforts
Other,enhancementOfImage
Other,established
Other,estimated
Other,evaluatedInVivo
Other,evaluation
Other,experiences
Other,expressed
Other,factor
Other,familialCancerClustering
Other,familialCancerClusteringInPatientsWithProlactinoma
Other,familyHistory
Other,familyImpact
Other,familyMember
Other,familyMemberAffectedWithCancer
Other,feasible
Other,features
Other,femalePatients
Other,femaleSibling
Other,filipinoWomen
Other,firstDiagnosisOfBreastCancer
Other,five
Other,fiveDoses
Other,fiveDosesOfAdjuvantTranstuzumab
Other,fluorescenceImagingExVivo
Other,follow-up
Other,formedByCo-encapsulationOfNear-infraredFluorophoreInPegylatedMicelles
Other,formulation
Other,formulationOfEffectiveManagementPlanForAt-riskWomen
Other,found
Other,fourTypesOfBreastCancer
Other,furtherDevelopment
Other,furthermoreDiagnosedWithPaAtEarlierAgeThanPatientsWithNegativeFamilyHistory
Other,furtherResearch
Other,generallyReserved
Other,glycosylation
Other,greater
Other,harmfulorHarmlessTissues
Other,hasApplied
Other,hasFound
Other,hasInconsistent
Other,haveDeveloped
Other,haveIntroduced
Other,haveReported
Other,haveReportedMainlyAfterMastectomy
Other,haveValidatedByClinicalStudiesInCardiotoxicityDiagnosisInPatientsTreatedWithHighDosesOfAnthracyclinesAloneInCombinationMainlyWithTrastuzumab
Other,healthcarePolicyMakers
Other,henceCurrentlyOnlyRoutinelyImplementedInScreeningOfWomenAtIncreasedRiskOfBreastCancer
Other,herDisease
Other,herPresentation
Other,heterogeneousCancerInFemalePatientsWorldwide
Other,higher
Other,higherResolution
Other,higherSuvmax
Other,highIndex
Other,highlyExpressed
Other,high-resolutionImages
Other,historyOfBreast-conservingSurgery
Other,homologousRecombinationPathway
Other,hormonalContraceptionUse
Other,howeverNon-ideal
Other,howeverSignificantlyLower
Other,howeverUnderutilized
Other,humanErrors
Other,I2
Other,identification
Other,identified
Other,images
Other,imaging
Other,imagingInvestigations
Other,imagingModalities
Other,imagingTechnique
Other,implemented
Other,importantCornerstone
Other,improvedBreastCancerOs
Other,improvedDetection
Other,included
Other,inconsistentResults
Other,increase
Other,increasedRiskWithUseOfLevonorgestrelIntrauterineSystem-bothOfPotentiallyImportantFindings
Other,Information
Other,initialResults
Other,inLongTermHasFound
Other,intravenousAdministrationOfOsteopontin-750Probe
Other,invasiveBreastCancer
Other,involved
Other,involvedInDnaDamageRegulation
Other,issues
Other,it
Other,itsMinimalSilverIonReleaseProfiles
Other,itsUse
Other,itsWidespreadUse
Other,lapatinibCombined
Other,largeCohortOfPatientsWithPituitaryAdenomasInOutpatientClinic
Other,largelyConsistent
Other,life
Other,locoregionalRadiotherapy
Other,longScanTime
Other,lowDiagnosticSensitivityForWomenWithDenseBreasts
Other,lungCancerInHuman
Other,majorConcerns
Other,malign
Other,mammographicImages
Other,Mammography
Other,management
Other,managementOfTumour-relatedSymptoms
Other,manyFeatures
Other,markedReduction
Other,massSpectrometry
Other,mayUsed
Other,mayUsedForTumourShrinkagePriorToSurgery
Other,measured
Other,medianAge
Other,medianAmount
Other,medianFollow-up
Other,meta-analysis
Other,Metastases
Other,metastaticDisease
Other,metastaticDiseaseOnPresentation
Other,misdiagnosis
Other,missed
Other,modifiedFactor
Other,moreCommonlyDiagnosed
Other,moreDirectional
Other,moreRecentlyHaveDeveloped
Other,moreSpecificApplications
Other,most
Other,mostCommonAgentsUsedInBreastCancerTreatment
Other,mostCommonCancer
Other,mostEffectiveTechniqueused
Other,mostInvasiveDisease
Other,mostSensitiveTest
Other,mostSensitiveTestForBreastCancerDetection
Other,multipleFactors
Other,multiresolutionResult
Other,mustAddressed
Other,mustAddressedDuringCancerGeneticCounselingConsultations
Other,mutationalStatusBesidesFamilyHistory
Other,mutations
Other,NAC
Other,nationwideRegistries
Other,necessary
Other,necessity
Other,needed
Other,neuralNetworkClassifier
Other,neuroma
Other,newValue-basedHealthcareParadigm
Other,non-ideal
Other,notablyDesigned
Other,novelPowerfulTechnique
Other,novelTargetedTherapeuticOptions
Other,observationalStudies
Other,observedVariation
Other,oneYear
Other,options
Other,osteopontin-basedProbe
Other,osteopontinPeptide
Other,ourExperience
Other,ourExperienceOfHigh-doseRadiotherapy
Other,ourFindings
Other,ourLiteratureReview
Other,outcomeOverCosts
Other,outcomesOfEstrogenReceptorPositive
Other,outpatientClinic
Other,overview
Other,particular
Other,patientDemographics
Other,patient'sOutcomeOverCosts
Other,patientsWithBreastCancerReceivingWithAnthracyclines
Other,patientsWithHistoryOfBreastSurgery
Other,patientsWithHistoryOfTranstuzumab-inducedCardiacDysfunction
Other,patientsWithLabc
Other,patientsWithProlactinoma
Other,percecnt
Other,percecntConfidenceIntervals
Other,performed
Other,performedFromInceptionToJanuary312018
Other,pharmacologicalInduction
Other,postmenopausalPatient
Other,potential
Other,preciseToolForTargetedTreatmentOfCancerIncludingBc
Other,preclinicalPhase
Other,presenceOfMetastaticDiseaseAtPresentation
Other,present
Other,previousBreast/axillarySurgery
Other,previousStudies
Other,primaryBreastCancerPatientsTreatedBetween01012010
Other,probe
Other,processing
Other,prolongedRecovery
Other,protected
Other,radicalSurgicalApproaches
Other,radiotherapy
Other,randomEffectsModel
Other,rare
Other,recentDanishCohortStudy
Other,recognized
Other,recorded
Other,reduction
Other,related
Other,relationship
Other,relativesOfPatientsWithPa
Other,repair
Other,reported
Other,reportedInSignificantlyHigherProportionOfPatientsWithPa
Other,required
Other,research
Other,respondents
Other,responsible
Other,results
Other,risk
Other,riskStratification
Other,role
Other,screening
Other,screeningBehavior
Other,screeningTools
Other,second
Other,segmentationAlgorithm
Other,sensitive
Other,seromaFormation
Other,shaped
Other,She
Other,signature
Other,significantAdvances
Other,significantlyHigherThanInFamiliesOfNfpaPatients
Other,similar
Other,similarTowaveletFilter
Other,sixGlycosylationSites
Other,smallMoleculeInhibitors
Other,soFarHasMainlyAssociatedWithMutationsInBrca1
Other,stageIiiBreastCaner
Other,standardizedImagingProtocol
Other,stratified
Other,strong
Other,strongFamilyHistoryOfCancer
Other,studies
Other,study
Other,subcutaneousBreastTumor
Other,subjectiveRisk
Other,subtype-specificSignature
Other,summaryHazardRatios
Other,targetedImmuneCell
Other,tenStudies
Other,test
Other,thanFamiliesOfPatientsWithNon-functioningPituitaryAdenomas
Other,the
Other,theirAbility
Other,theirAbilityOfPrognosisPredictionInTheirOriginallyTargetedPopulationsOfBreastCancer
Other,theirBeliefsRegardingCancerCausation
Other,theirEmergingRole
Other,theirExperiencesLivingWithSister
Other,theirInhibition
Other,theirOriginallyTargetedPopulationsOfBreastCancer
Other,thematicAnalysis
Other,themselves
Other,therapeuticBenefits
Other,thereforeHasAppliedToEarlyIdentification
Other,theResulting
Other,They
Other,third-degree
Other,time
Other,tnbcCells
Other,total
Other,Transcripts
Other,transferable
Other,traumaticNeuroma
Other,treatment
Other,troponins
Other,tumorDetectability
Other,tumorImaging
Other,tumor-to-backgroundRatios
Other,Ulceration
Other,understand
Other,understanding
Other,unresectedLocallyAdvancedBreastCancer
Other,unusual
Other,update
Other,updateOnRiskFactorsForSeromaProductionAfterBreastCancerSurgery
Other,urgentlyNeeded
Other,use
Other,used
Other,useOfAdvancedImagingExaminations
Other,value
Other,variableMolecularMechanismsOfCarcinogenesis
Other,veryComplexDisease
Other,visuallyDetectable
Other,we
Other,widerPopulationOfTnbcPatients
Other,woundDrainsPlacedInBreast
Other,x-rayMammography
Other,youngPatients
Performance,diagnosticPerformance
Performance,diagnosticPerformanceOfCxcr4-directedPetImagingInPatientsWithBreastCancer
Performance,performance
Performance,thusWouldCrucialForApplicationOfPreventiveStrategies
PET,cxcr4-targetedPetImaging
PET,petImaging
PET,recentlyIntroducedCxcr4-targetedPetProbe68ga-pentixafor
Prognostic,numerousGene-expression-basedPrognosticSignatures
Prognostic,strongIndependentPrognosticFactor
Prognostic,subtype-specificPrognosticSignatures
Protocols,abbreviatedMriProtocols
Protocols,mriProtocols
Protocols,overviewOfAbbreviatedBreastMriProtocols
Signal,additionalIndicator
Signal,indicator
Signal,secondaryConfirmationOfSignalAccumulationUsingNearInfraredFluorescentImaging
Signal,signalIntensity
Signatures,collectedSignatures
Signatures,signatures
Species,human
Species,nudeMice
Species,patient
Species,patients
Species,People
Species,women
Vitro,bindingToBreastCancerCellsInVitro
Vitro,infraredFluorescentImagingInTripleNegativeInVitro
Vitro,selectiveAccumulationOfFluorescentOsteopontinInVitroAndInVivo